Teva Pharmaceutical Industries Limited (TLV:TEVA)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
10,200
+70 (0.69%)
At close: Jan 14, 2026
34.58%
Market Cap117.20B
Revenue (ttm)55.55B
Net Income (ttm)2.36B
Shares Outn/a
EPS (ttm)2.04
PE Ratio49.64
Forward PE12.28
Dividendn/a
Ex-Dividend Daten/a
Volume1,420,105
Average Volume1,354,290
Open10,120
Previous Close10,130
Day's Range10,060 - 10,310
52-Week Range4,865 - 11,100
Beta0.66
RSI62.08
Earnings DateJan 28, 2026

About TLV:TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]

Sector Healthcare
Founded 1901
Employees 35,686
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol TEVA
Full Company Profile

Financial Performance

In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.

Financial numbers in USD Financial Statements

News

Teva (TEVA) Gains FDA Approval for Ajovy in Pediatric Migraine Treatment

Teva (TEVA) Gains FDA Approval for Ajovy in Pediatric Migraine Treatment

5 hours ago - GuruFocus

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

PARSIPPANY, N.J. and TEL AVIV, Israel, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the N...

5 hours ago - GlobeNewsWire

Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript

Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript

1 day ago - GuruFocus

Judge Denies Teva Bid To Pause Paragard Copper Contraceptive Device Lawsuit Trial

A Georgia federal judge on Monday reportedly denied Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) a request to delay the first trial in thousands of lawsuits alleging its Paragard intrauterine dev...

1 day ago - Benzinga

Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug

Teva Pharmaceutical Industries Ltd . (NYSE: TEVA) and Royalty Pharma plc (NASDAQ: RPRX) announced on Sunday a funding agreement of up to $500 million to accelerate the clinical development of Teva’s...

2 days ago - Benzinga

Teva Taps Royalty Pharma For $500M To Advance Skin Disease Drug

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Royalty Pharma plc (NASDAQ: RPRX) announced on Sunday a funding agreement of up to $500 million to accelerate the clinical development of Teva's an...

2 days ago - Benzinga

Why Investors Are So Optimistic on Teva

Teva Pharmaceuticals stock jumped Monday after the drugmaker issued upbeat guidance and targets for the years ahead.

2 days ago - Barrons

TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug

Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-'408, while keeping global commercial control.

2 days ago - Nasdaq

Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

2 days ago - Nasdaq

Teva Pharmaceutical (TEVA) Projects Higher EPS and Revenue Outlook

Teva Pharmaceutical (TEVA) Projects Higher EPS and Revenue Outlook

2 days ago - GuruFocus

Teva (TEVA) Secures $500M Funding for Vitiligo Therapy Development

Teva (TEVA) Secures $500M Funding for Vitiligo Therapy Development

2 days ago - GuruFocus

Royalty Pharma And Teva Broaden Collaboration To Advance Potential Vitiligo Treatment

(RTTNews) - Royalty Pharma plc. (RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), have announced a funding agreement of up to $500 million to advance the...

2 days ago - Nasdaq

Teva Pharmaceutical (TEVA) Projects Revenue Between $16.8B and $17B for FY25

Teva Pharmaceutical (TEVA) Projects Revenue Between $16.8B and $17B for FY25

3 days ago - GuruFocus

Teva (TEVA) Projects Significant Growth in FY30 with Strong Cash Flow

Teva (TEVA) Projects Significant Growth in FY30 with Strong Cash Flow

3 days ago - GuruFocus

Teva Pharmaceutical (TEVA) Projects Strong FY30 Financial Performance

Teva Pharmaceutical (TEVA) Projects Strong FY30 Financial Performance

3 days ago - GuruFocus

TEVA Expects FY27 EBITDA Growth and Net Cash Flow Increase

TEVA Expects FY27 EBITDA Growth and Net Cash Flow Increase

3 days ago - GuruFocus

TEVA Forecasts Growth in FY26 Adjusted EBITDA and Free Cash Flow

TEVA Forecasts Growth in FY26 Adjusted EBITDA and Free Cash Flow

3 days ago - GuruFocus

Royalty Pharma And Teva Announce $500 Mln Funding Agreement For TEV-408 Development

(RTTNews) - Royalty Pharma plc (RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), have entered into a funding agreement of up to $500 million to accelerat...

3 days ago - Nasdaq

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Richard Francis, Teva's President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time) Richard F...

3 days ago - GlobeNewsWire

Royalty Pharma (RPRX) Partners with Teva for $500M Drug Development Funding

Royalty Pharma (RPRX) Partners with Teva for $500M Drug Development Funding

3 days ago - GuruFocus